Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지

Antiangiogenic Effect of $AS_2O_3$ on the New Vessels Induced by bFGF in the Rat Cornea

랫드 각막에서 bFGF(basic Fibroblast Growth Factor)로 유발시킨 신생혈관에 대한 $AS_2O_3$의 혈관신생 억제 효과

  • 김용수 (강원대학교 수의학과 외과학교실) ;
  • 서강문 (강원대학교 수의학과 외과학교실)
  • Published : 2001.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

This study was performed to evaluate the effects of $AS_2O_3$ upon antiangiogenesis in rat cornea, to examine it\`s possible application as an anticancer drug and to provide basic data for further studies of antiangiogenetic mechanism of $AS_2O_3$ . Angiogenesis was induced by cornea micropocket assay, as previously described. Sixteen of forty-eight eyes of Sprague-Dawley rats were randomly assigned to one of three groups, namely, only a bFGF group(control group), and a group treated by $AS_2O_3$ ($AS_2O_3$ group). After pellet implantation, we measured the number of new vessels, vessel length and clock hour of neovascularization, and area of neovascularization was determined using a mathematical formula. New vessels growing began at day 3, number of vessels in $AS_2O_3$ group were significantly more less than those in control group (p<0.05). The length of vessels of $AS_2O_3$ group was significantly shorter than that of control group after day 3(p<0.05). The clock hours of all group were slowly increased at all days but $AS_2O_3$ group was inhibited more than control group. Neovascularization areas of $AS_2O_3$ group were more significantly inhibited than those of control group (p<0.05). This study showed that $AS_2O_3$ had powerful antiangiogenetic effects and it would be useful in the choice of anticancer drug.

Keywords

References

  1. Oncologist v.6 Introduction : The history of arsenic trioxide in cancer therapy Antman K
  2. Toxicol Appl Pharmacol v.159 Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways Barchowsky A;Roussel R;Klei L;James P;Ganju N;Smith K;Dudek E
  3. Nature v.390 Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Boehm T;Folkman J;Browder T;O'Reilly M
  4. Cell v.79 Intergrin ${\alpha}_v{\beta}_3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Brooks P;Montgomery A;Rosenfeld M;Reisfeld R;Hu T;Klier G;Cheresh D
  5. Science v.208 Inhibition of cell motility by interferon Brouty-Doye D;Zetter BR
  6. FASEB J v.13 Interleukin-18 acts an angiogenesis and tumor suppressor Cao R;Farnebo J;Kurimoto M;Cao Y
  7. Proc Natl Acad Sci v.91 Thalidomide is an inhibitor of angiogenesis D'Amato R;Loughnan M;Flynn E;Folkman J
  8. Cell v.87 Blood vessel formation : what is its molecular basis? Fokman J;D'Amore P
  9. Cell v.86 Pattern and emerging mechanisms of the angiogenic switch during tumorigenesis Hanahan D;Folkman J
  10. Blood v.94 Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway Jing Y;Dai J;Chalmers-Redman R;Tatton W;Waxman S
  11. Invest Ophthamol Vis Sci v.37 A model of angiogenesis in the mouse cornea Kenyon B;Voest E;Chen C;Flynn E;Folkman J
  12. Exp Eye Res v.64 Effect of thailidomide and related metabolites in a mouse corneal model of neovascularization Kenyon B;Browne F;D'Amato R
  13. Nature v.362 Inhibition of vascular endothelial growth factorinduced angiogenesis suppress tumor growth in vivo Kim K;Li B;Winer J;Armanini M;Gillett N;Phillips H;Ferrara N
  14. Blood v.89 Delicious Poison: arsenic trioxide for the treatment of leukemia Kwong YL;Todd D
  15. Blood v.90 Comparative activity of melarsoprol and srsenic trioxide in chronic B-cell leukemia Lines Konig A;Wrazel L;Warrel Jr R;Rivi R;Pandolfi P;Jakubowski A;Gabrilove J.
  16. Cancer Res v.59 Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown Lew Y;Brown S;Griffin R;Song C;Kim J
  17. Proc Natl Acad Sci USA v.96 Millimeter-scale positioning of a nerve- growth-factor source and biological activity in the brain Mahoney M;Slaltzman W
  18. Oncologist v.61 Arsenic trioxode : An emerging therapy of multiple myeloma Munshi N
  19. Cell v.79 Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastates by a Lewis lung carcinoma O'Reilly M;Holmgren L;Shing Y;Chen C;Rosenthal R;Moses M;Lane W;Cao Y;Sage E;Folkman J
  20. Methods Enzymol v.198 Assay and purification naturally occurring inhibitor of angiogenesis Polverini P;Bouck N;Raztinejad F
  21. Proc Natl Acad Sci USA v.97 Petinoic acid(RA) and $As_2O_3$ treatment in transgenic medels of acute promyelocytic leukemia(APL) unravel the distinct nature of the leukemogenic preocess induced by thr PML-RAR$_{\alpha}$ and PLZF-RAR$_{\alpha}$ oncoproteins Rego E;He L.Z;Warrell R;Wang Z.G;Pandilfi P
  22. Nature v.386 Mechanisms of angiogenesis Risau W.
  23. Blood v.96 Arsenic trioxide induces dose- and time- dependent apoptosis of endothelium and may exert an antileukemic effect via inhinition of angiogenesis Roboz G;Dias S;Lam G;lane W;Soignet S;Warrel Jr R;Rafii S
  24. Oncologist v.6 Risk/benefit profile of arsenic trioxide Rust D;Soignet S
  25. J Vet Sci v.2 Angiogenesis effects of nerve growth factor(NGF) on rat corneas Seo K;Choi J;Park M;Rhee C
  26. Blood v.89 Use of arsenic trioxide($As_2O_3$) in the treatment of acute promyelocytic leukemia(APL): II. clinical efficacy and pharmacokinetics in relapsed patients Shen Z-X;Chen G-Q;Ni J-H;Li X-S;Xiong S-M;Qiu Q-Y;Zhu J;Tang W;Sun G-L;Yang K-Q;Chen Y;Zhou L;Fang Z-W;Wang Y-T;Ma J;Zhang P;Zhang T-D;Chen S-J;Chen Z;Wang Z-Y
  27. Oncologist v.6 Clinical experience of arsenic trioxide in relapsed acute promyelocytic Soignet S
  28. NEJM v.339 Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide Soignet S;Maslak P;Wang Z-G;Jhawar S;Calleja E;Dardashti L;Corso D;DeBlasio A;Garbrilove J;Scheinberg D;Pandolfi P;Warrell R
  29. Oncologist v.6 History of the development of arsenic derivatives in canser therapy Waxman S;Anderson K
  30. Modern Pathology v.13 Pathologic, cytogenetic and molecular assesment of acute promyelocytic leukemia patients treated with arsenic trioxide($As_2O_3$) Zhang T;Westervelt P;Hess J
  31. J Natl Cancer Inst v.91 Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations Zhu X-H;Shen Y-L;Jing Y-K;Cai X;Jia P-M;Huang Y;Tang W;Shi G-Y;Sun Y-P;Dai J;Wang Z-Y;Chen S-J;Zhang T-D;Waxman S;Chen Z;Chen G-Q
  32. 대한안과학회지 v.38 Basic fibroblast growth factor에 의해 유도된 쥐의 각막혈관생성에 있어서 urokinase plaminogen activatort 수용체에 대한 길항체의 억제효과 이자영;정성근;Hwang D
  33. 대한안과학회지 v.37 각막혈관생성에 있어서 Urokinase plasminogen activator수용체에 대한 길항체의 억제효과 정성근;이자영;Hwang D